Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.
| Website: | www.pieris.com |
| Email: | kelman@pieris.com |
| Main Phone: | +1 857 246-8998 |
| Address: | 255 State Street |
| Address 2: | 9th floor |
| State: | MA |
| City / Town: | Boston |
| Country: | US |
| Postal Code: | 02109 |
| Exchange: | NSC |
| CEO: | Stephen S. Yoder |
| Employees: | 127 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
A technical view of four stocks that appear to be at or near a breakout point.
Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)
Collaboration on 3 immuno-oncology programs
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.
| Website: | www.pieris.com |
| Email: | kelman@pieris.com |
| Main Phone: | +1 857 246-8998 |
| Address: | 255 State Street |
| Address 2: | 9th floor |
| State: | MA |
| City / Town: | Boston |
| Country: | US |
| Postal Code: | 02109 |
| Exchange: | NSC |
| CEO: | Stephen S. Yoder |
| Employees: | 127 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
A technical view of four stocks that appear to be at or near a breakout point.
Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)
Collaboration on 3 immuno-oncology programs
| Last Price 2.12 | Change $ -0.12 | Change % -5.36 | Tick N/A |
| Bid 2.11 | Bid Size 600.00 | Ask 2.12 | Ask Size 500.00 |
| Open 2.26 | High 2.27 | Low 2.10 | Prev Close 2.24 |
| Last Trade | Volume 357,077 | 52 Wk Hi 5.64 | 52 Wk Low 1.61 |
| Market Cap 111.1 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 52,398,600.00 | EPS (TTM) -0.27 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 1 | 5 |
| Number of Buys | 1 | 5 |
| Number of Sells | 0 | 0 |
| Net Activity | 10000 | 535000 |
| Last 10 Buys | Shares |
|---|---|
| James A. Geraghty | 1,000 |
| Allan Reine | 1,000 |
| James A. Geraghty | 1,000 |
| Allan Reine | 1,000 |
| Louis Matis | 1,000 |
| Darlene M. Deptula-Hicks | 1,000 |
| Louis Matis | 1,000 |
| Stephen S. Yoder | 1,000 |
| Chau Q. Khuong | 1,000 |
| Chau Q. Khuong | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| N/A | 0 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 13 | 13 | 13 | 13 |
| Low Target Price Estimate | 8 | 8 | 8 | 8 |
| Mean Target Price Estimate | 11.25 | 11.25 | 11.25 | 11.25 |
| Standard Deviation | 2.22 | 2.22 | 2.22 | 2.22 |
| Date of Most Recent Estimate | 05/14/18 | 05/14/18 | 05/14/18 | 05/14/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| DEFA14A | Additional proxy soliciting materials - definitive | 2 | 2018-06-14 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 74 | 2018-06-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 25 | 2018-06-06 |
| SC 13D/A | Amendment to a SC 13D filing | 10 | 2018-05-29 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-16 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 231 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 10 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 29 | 2018-05-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-02 |
| SC 13D/A | Amendment to a SC 13D filing | 10 | 2018-05-02 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait